O TYM ODCINKU
What if the future of peptide therapy isn't just about which peptide you use — but where you deliver it?
In this episode of The Energy Code, Dr. Mike Belkowski explores one of the most intriguing frontiers in peptide research: intranasal delivery and its potential to create a more brain-oriented route for peptides that influence neurological function, tissue repair, stress regulation, and mitochondrial biology.
The episode begins with the science of nose-to-brain delivery, including the olfactory and trigeminal pathways, systemic absorption through the nasal mucosa, and the possibility of partially circumventing one of neuroscience's biggest obstacles: the blood-brain barrier. But Mike also explains why “intranasal” alone tells us very little about pharmacology — formulation, stability, deposition, device design, concentration, and nasal anatomy can all dramatically affect what actually happens.
Then he breaks down four intriguing formulations: BPC-157, oxytocin, MOTS-c, and MOTS-c + SS-31.
BPC-157 is explored as the repair and regeneration hypothesis, with preclinical research involving traumatic brain injury, ischemia, spinal cord injury, vascular signaling, inflammation, and tissue repair. Oxytocin represents the neuromodulation hypothesis and has by far the strongest direct human intranasal evidence of the four.
MOTS-c takes the conversation directly into mitochondrial medicine. As a mitochondrial-derived signaling peptide, it may help cells recognize and adapt to metabolic stress — and emerging animal research raises fascinating questions about its potential neurological applications. Finally, Mike explores what may be the most intriguing mechanistic pairing: MOTS-c + SS-31, combining cellular metabolic adaptation with direct mitochondrial membrane and cardiolipin support.
The key question isn't simply “What does this peptide do?”
It's: Can we get the peptide to the place where we need it for it to be most effective?
(Educational content only, not medical advice.)
-
Key Quotes From Dr. Mike:
“The biggest question in peptide medicine... is not simply, what does this peptide do? Rather, can we get this peptide to the place where we need it for it to be most effective?”
“The fact that BPC-157 has interesting TBI data does not mean intranasal BPC-157 has been demonstrated to treat concussion.”
“Oxytocin may amplify or reshape social processing rather than simply producing a universally positive emotional state.”
“There's a possible connection between oxytocin and the body's ability to shift from a defensive state toward a state of social safety and physiological recovery.”
“MOTS-c biology may be therapeutically interesting in the brain, and intranasal delivery may be one potential strategy for overcoming the blood-brain barrier problem.”
“SS-31 essentially targets that energetic crisis at the mitochondrial membrane itself (via cardiolipin)."
“SS-31 helps stabilize the mitochondrial hardware. MOTS-c helps regulate the cellular software.”
-
Key Points
⚡ Intranasal delivery may offer peptides both rapid systemic absorption and potential access toward the CNS through olfactory and trigeminal pathways.
⚡ Nose-to-brain delivery could be particularly interesting for peptides targeting cognition, neuroinflammation, neurological injury, and mitochondrial dysfunction.
⚡ Intranasal delivery itself is not theoretical—several peptide hormones already have established nasal formulations—but that does not validate every investigational peptide as an effective nasal therapy.
⚡ BPC-157 is the repair and regeneration hypothesis: preclinical research suggests effects involving vascular signaling, nitric oxide, inflammation, tissue integrity, and neurological injury.
⚡ Animal studies have reported intriguing BPC-157 findings in traumatic brain injury, cerebral ischemia, and spinal cord injury—but convincing human neurological and intranasal efficacy data are lacking.
⚡ Oxytocin is the neuromodulation hypothesis and has the strongest direct human intranasal research foundation of the four.
⚡ Intranasal oxytocin can alter central oxytocin physiology, but its effects on social behavior, emotion, stress, and pain appear highly context-dependent rather than universally beneficial.
⚡ MOTS-c is the metabolic resilience hypothesis: it functions as a mitochondrial-derived signal involved in AMPK, stress adaptation, metabolism, inflammation, antioxidant responses, and mitochondrial biology.
⚡ Preclinical research suggests MOTS-c may have neurological relevance in traumatic brain injury, cognitive impairment, neuroinflammation, and neuropathic pain.
⚡ A modified cell-penetrating MOTS-c analog has demonstrated brain distribution after intranasal administration in mice—but this should not be conflated with evidence for ordinary native intranasal MOTS-c.
⚡ MOTS-c + SS-31 is the mitochondrial rescue hypothesis: the two peptides potentially address mitochondrial dysfunction through very different mechanisms.
⚡ SS-31 targets cardiolipin and mitochondrial membrane biology, while MOTS-c influences metabolic signaling, gene expression, AMPK, inflammation, and cellular stress adaptation.
⚡ A simple analogy: SS-31 helps stabilize the mitochondrial hardware; MOTS-c helps regulate the cellular software.
⚡ There is currently no compelling clinical evidence demonstrating that an intranasal MOTS-c + SS-31 blend produces synergistic effects in humans.
⚡ The real promise of intranasal peptides isn't simply avoiding needles—it's potentially changing where a peptide goes, how quickly it gets there, and which biological systems it can influence.
-
Episode timeline
00:00 — Why We're Revisiting Intranasal Peptides
01:30 — BPC-157, Oxytocin, MOTS-c & MOTS-c + SS-31
03:10 — Why Intranasal Delivery Is So Interesting
06:39 — The Four Peptide Formulas
08:00 — Evidence vs. Mechanism: An Important Distinction
08:45 — How Intranasal Peptides Enter the Body
09:37 — The Olfactory & Trigeminal Pathways
10:34 — Can Peptides Bypass the Blood-Brain Barrier?
12:27 — Why Formulation & Nasal Deposition Matter
13:12 — BPC-157: The “Healing Peptide” Explained
14:38 — BPC-157 & Traumatic Brain Injury
15:56 — Cerebral Ischemia & Neurological Recovery
16:59 — BPC-157 & Spinal Cord Injury
17:48 — Why Intranasal BPC-157 Is Still Highly Speculative
19:43 — Could BPC-157 Be Interesting for Concussion?
21:30 — Oxytocin: The Strongest Intranasal Evidence
23:25 — Does Intranasal Oxytocin Actually Reach the Brain?
24:17 — PET Imaging Tracks Intranasal Oxytocin
25:56 — Social Cognition, Trust & Emotional Processing
28:08 — Oxytocin, Stress & the Autonomic Nervous System
29:09 — Oxytocin & Pain
29:53 — Why Oxytocin Isn't Simply the “Love Hormone”
30:41 — MOTS-c: The Mitochondrial Signaling Peptide
31:30 — How MOTS-c Communicates With the Nucleus
32:26 — MOTS-c & Metabolic Stress
33:16 — MOTS-c & Traumatic Brain Injury
34:20 — Intranasal MOTS-c & the Blood-Brain Barrier Problem
35:20 — MOTS-c, Memory & Neuroinflammation
36:35 — Neuropathic Pain & Broader Metabolic Effects
37:09 — A Surprising New Role for MOTS-c
37:51 — Why Intranasal MOTS-c Is So Interesting
38:38 — MOTS-c + SS-31: The Mitochondrial Rescue Hypothesis
38:56 — How SS-31 Targets Cardiolipin
41:10 — SS-31's Human & Regulatory Evidence
41:30 — SS-31 & Traumatic Brain Injury
42:11 — Mitochondrial Dysfunction After Concussion
43:15 — MOTS-c + SS-31: Hardware Meets Software
44:39 — How the Two Peptides Could Complement Each Other
45:12 — Why the Combination Is Still a Hypothesis
47:39 — The Four Intranasal Peptides Compared
49:46 — The Real Promise of Intranasal Peptides
50:03 — The Biggest Question in Peptide Medicine
50:38 — Final Thoughts
-
BioLight Labs
Introducing Four NEW Intranasal Peptides...
- BPC-157
- Oxytocin
- MOTS-c
- MOTS-c + SS-31
-
Dr. Mike's #1 recommendations:
Deuterium depleted water: Litewater (code: DRMIKE)
EMF-mitigating products: Somavedic (code: BIOLIGHT)
Blue light blocking glasses: Ra Optics (code: BIOLIGHT)
Grounding products: Earthing.com
-
Stay up-to-date on social media:
Dr. Mike Belkowski:
BioLight Labs:
BioLight:
